Funded Biotechnology Startups in Israel
Across the 50 biotech entries shown (latest dated 2026-03-07 and earliest dated 2022-11-17), the largest disclosed round is Enlivex Therapeutics’ $212M on…
Across the 50 biotech entries shown (latest dated 2026-03-07 and earliest dated 2022-11-17), the largest disclosed round is Enlivex Therapeutics’ $212M on 2025-11-24, which dwarfs the next-largest disclosed amounts (e.g., MitrAssist at $100M on 2023-09-26 and InSightec at $150M on 2024-06-18). The table is also stage- and amount-uneven: while several companies report mid-to-high eight figures or more (CytoReason $80M on 2024-07-17; Omnix Medical $25M on 2025-10-15), many disclosed rounds sit far lower, including multiple entries at $3M–$5M.
Several clusters stand out. First, “Series Unknown” appears 33 times, far more than any named stage (e.g., “Series A” appears 6 times; “Seed” appears 4 times; “Series B” appears 5 times; “Series C” appears 3 times; “Series D” appears once; “Angel” once). Second, location repeats heavily around major Israeli metro areas, especially Tel Aviv and nearby centers: Tel Aviv appears directly for entries like RedHill Biopharma (2025-10-20, $4M) and Purple Biotech (2024-12-03, $3M), while Ness Ziona shows up multiple times (BIOMx $3M on 2025-12-29; Enlivex Therapeutics $212M on 2025-11-24; DOT Compliance $18M on 2024-04-15). Finally, there is a tight recent window in late 2025: at least six rounds with disclosed amounts close between 2025-10-15 and 2025-12-29 (e.g., Omnix Medical $25M on 2025-10-15; RedHill Biopharma $4M on 2025-10-20; Enlivex Therapeutics $212M on 2025-11-24; BIOMx $3M on 2025-12-29).
Most recent rounds
50 shownRelated listings
Frequently asked
What is the largest disclosed round in this Israel biotech list, and how does it compare to the rest of the disclosed amounts?
Enlivex Therapeutics’ disclosed $212M round on 2025-11-24 is the clear outlier; the next-largest disclosed entries in the table are far lower (for example, InSightec’s $150M on 2024-06-18 and MitrAssist’s $100M on 2023-09-26).
How dominant is “Series Unknown” in these 50 rows, compared with named stages?
“Series Unknown” is the most common label at 33 of 50 rows. Named stages appear far less often: Series A (6), Series B (5), Seed (4), Series C (3), and singletons include Series D (1) and Angel (1).
Are there notable temporal clusters near the top of the list (most recent months)?
Yes. Between 2025-10-15 and 2025-12-29, multiple disclosed rounds fall in a tight window, including Omnix Medical ($25M on 2025-10-15), RedHill Biopharma ($4M on 2025-10-20), Enlivex Therapeutics ($212M on 2025-11-24), and BIOMx ($3M on 2025-12-29).
Do specific cities repeat often enough to suggest a geographic concentration?
Tel Aviv-area locations recur frequently, with “Tel Aviv” explicitly listed on several entries such as RedHill Biopharma (Tel Aviv, 2025-10-20, $4M) and Purple Biotech (Tel Aviv, 2024-12-03, $3M). Ness Ziona also clusters multiple times: BIOMx (2025-12-29, $3M), Enlivex Therapeutics (2025-11-24, $212M), and DOT Compliance (2024-04-15, $18M).
Which outliers are worth attention beyond the top dollar amount?
Several entries sit in very different parts of the distribution. The smallest disclosed amount is InnoCan Pharma at $450K on 2026-03-07, while large rounds concentrate elsewhere such as MitrAssist ($100M on 2023-09-26), CytoReason ($80M on 2024-07-17), and InspireMD ($114M on 2023-05-15).
Does the stage mix change in the most recent entries versus older ones?
The most recent rows (2026-03-07 down to 2025-08-27) include only one named “Series A” entry in that slice (Starget Pharma at $18M on 2026-02-18), while many others are labeled “Series Unknown” such as InnoCan Pharma ($450K on 2026-03-07) and MeMed ($2M on 2026-01-12). In older rows, named stages appear more visibly, including Series B (DOT Compliance, $18M on 2024-04-15; CytoReason, $80M on 2024-07-17).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.